Ph3 Study of Bomedemstat (MK-3543) vs Hydroxyurea in Essential Thrombocythemia Participants
Phase III Clinical Trial
A Phase 3 Randomized Double-blind Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Na�ve Essential Thrombocythemia Participants (MK3543-007)